For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not negatively impact survival, according to a study published online Jan. 2 in Blood.

Among patients hospitalized with COVID-19, particularly those who were also receiving noninvasive ventilation or invasive mechanical ventilation, dexamethasone was associated with reduced mortality.

Dexamethasone 0.5mg, 0.75mg, 4mg, 6mg; tabs. Naturally occurring glucocorticoids, (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in ...

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed ...

Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that a new real-world study on melflufen (melphalan flufenamide, branded in Europe as Pepaxti) plus ...

Objective: To compare the efficacy and tolerability of dexamethasone-21-palmitate and mepivacaine alone and in combination in the acute treatment of facet syndrome. Results: In all three groups ...

Corticosteroid therapy must be tapered because of its interactions with the hypothalamic-pituitary-adrenocortical (HPA) axis. The hypothalamus secretes corticotropin releasing factor, which acts ...

Opens in a new tab or window Modifying the quadruplet regimen of isatuximab, bortezomib, lenalidomide, and dexamethasone could allow older, frail patients with transplant-ineligible multiple ...

FRIDAY, Jan. 24, 2025 (HealthDay News) -- For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not negatively impact survival ...

The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly ...